$-0.09
(Market cap
$192 Mln
Revenue (TTM)
$71 Mln
P/E Ratio
--
P/B Ratio
15.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
33.74
-
EV/EBITDA
-0.2
-
Debt to Equity
1.8
-
Book Value
$--
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
24,225,339
10 Years Aggregate
CFO
$-133.61 Mln
EBITDA
$-138.92 Mln
Net Profit
$-194.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Exagen (XGN)
| 22.2 | 68.9 | 48.3 | -22.2 | 42.3 | -11.6 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Exagen (XGN)
| 48.3 | 104.8 | -17.1 | -79.4 | -11.9 | -48.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Exagen (XGN)
|
7.4 | 191.9 | 71.1 | -18.9 | -19.3 | -127.6 | -- | 15.7 |
| 526.0 | 7,065.2 | 2,595.0 | 275.0 | 14.1 | 30.4 | 26.9 | 8.4 | |
| 121.3 | 11,869.0 | 6,206.1 | 621.0 | 18.6 | 16.2 | 20.2 | 4.6 | |
| 28.9 | 7,433.4 | 2,578.1 | -142.0 | -6.3 | -32.8 | -- | 22.4 | |
| 12.5 | 4,764.2 | 1,584.8 | 50.6 | 4.9 | 3.4 | 95.9 | 3.3 | |
| 223.3 | 3,707.8 | 1,559.0 | 140.3 | 12.1 | 12.6 | 26.3 | 3.3 | |
| 24.0 | 3,549.9 | 5,693.5 | 209.6 | 6.0 | 16.2 | 18 | 2.8 | |
| 75.7 | 6,045.6 | 2,268.9 | -21.1 | 4.7 | -4.5 | -- | 5.5 | |
| 19.3 | 5,584.8 | 1,216.2 | 163.5 | 33.5 | 25.7 | 33.7 | 8.2 | |
| 173.1 | 10,460.5 | 5,486.7 | 378.7 | 9.2 | 16.2 | 28.2 | 4.3 |
Shareholding Pattern
View DetailsAbout Exagen (XGN)
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex... rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Read more
-
Executive Chairman of the Board of Directors
Dr. Tina S. Nova Ph.D.
-
Executive Chairman of the Board of Directors
Dr. Tina S. Nova Ph.D.
-
Headquarters
Vista, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Exagen (XGN)
What is the current share price of Exagen Inc (XGN) Today?
The share price of Exagen Inc (XGN) is $7.43 (NASDAQ) as of 28-Aug-2026 13:39 EDT. Exagen Inc (XGN) has given a return of 42.34% in the last 3 years.
What is the current PB & PE ratio of Exagen Inc (XGN)?
Since, TTM earnings of Exagen Inc (XGN) is negative, P/E ratio is not available.
The P/B ratio of Exagen Inc (XGN) is 15.71 times as on 21-Aug-2026, a 344 premium to its peers’ median range of 3.54 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.57 |
7.51 |
2024 |
-4.94 |
7.82 |
2023 |
-1.50 |
1.56 |
2022 |
-0.87 |
0.97 |
2021 |
-7.35 |
2.32 |
What is the 52 Week High and Low of Exagen Inc (XGN)?
The 52-week high and low of Exagen Inc (XGN) are Rs 12.23 and Rs 2.60 as of 29-Aug-2026.
What is the market cap of Exagen Inc (XGN)?
Exagen Inc (XGN) has a market capitalisation of $ 192 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Exagen Inc (XGN)?
Before investing in Exagen Inc (XGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.